AI assistant
Sending…
Marker Therapeutics, Inc. — Director's Dealing 2016
Jan 28, 2016
35150_dirs_2016-01-28_0aafc9bf-07d6-413e-8f93-0339974a772a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2016-01-26
Reporting Person: Wasserman Frederick Gerald (Director)
More from Marker Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Mar 20
Annual Report
2026
Mar 20
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 18
Regulatory Filings
2026
Feb 9
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Major Shareholding Notification
2025
Nov 17